Skip to content
Screener

Discontinued — last reported Q4 '25

Total Revenue at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$12.97B+5.7%
Gilead Sciences logo
Gilead SciencesGILD
$7.8B+10.2%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$44.21M+168%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$10.86M+3.8%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$7.66M-46.2%

Other financials

Income statement

See full
Operating income-$26.9M-17.9%
Net income-$25.0M-17.6%
EPS (diluted)-$0.63+27.6%

Balance sheet

See full
Cash & equivalents$301.9M+944%
Total debt$9.8M-25.5%
Total equity$347.5M+133%
Total assets$368.6M+118%

Cash flow

See full
Operating cash flow-$20.4M+11.4%
CapEx$415.0K-60.7%
Free cash flow-$20.8M+13.6%

Valuation

See full
Market cap$550.99M+783%
Enterprise value$258.93M+455%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity-0.1×
Current ratio24.2×+10.3×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Artiva Biotherapeutics, Inc.’s 10-K, filed March 10, 2026.

Filed
Mar 10, 2026, 4:09 PM EDT
Fiscal year
FY2025
Accession
0001193125-26-100135
Line itemYEAR ENDED DECEMBER 31, 2025YEAR ENDED DECEMBER 31, 2024
Revenue$251
Less:
AB-101 (AlloNK)32,37919,978
Other programs(a)23330
Personnel-related39,28530,465
Other(b)18,12316,760
Other income, net5,9451,909
Net loss$(83,865)$(65,373)

Item 16. Form 10-K Summary

FAQ

What is Artiva Biotherapeutics, Inc.'s total revenue?
Artiva Biotherapeutics, Inc. (ARTV) reported total revenue of $0 in Q4 2025.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Artiva Biotherapeutics, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude